Merck's Q1 2014 earnings call highlighted solid operational performance, driven by growth in key brands like Januvia, Isentress, and immunology products.  Management reiterated their commitment to innovation,  emphasizing clinical progress in oncology and hepatitis C and securing regulatory approvals like GRASTEK.  While there were some headwinds from loss of exclusivity and inventory adjustments, the strong pipeline and  focus on key markets suggest a positive outlook for the short term.
[1]
